Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. [PDF]
BMC Cancer, 2015 The impact of KRAS signaling on cancerous inhibitor of protein phosphatase 2A (CIP2A) expression has not yet been explored. We investigated the impact of KRAS on CIP2A expression in colorectal cancer patients after colorectal liver metastasectomy.
Chen KF +11 more
europepmc +5 more sources
Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity. [PDF]
J Biol Chem, 2014 Background: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is overexpressed in most types of human cancer. Results: Depletion of CIP2A prolongs cell division time and CIP2A interacts with NIMA-related kinase 2 (NEK2) during G2/M phase to ...
Jeong AL +7 more
europepmc +5 more sources
Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. [PDF]
Transcription, 2012 Cancerous inhibitor of protein phosphatase 2A (CIP2A) has been identified as a proto-oncogene that is overexpressed in various types of human cancers. CIP2A acts by inhibiting protein phosphatase 2A-dependent destabilization of c-Myc, resulting in increased cell proliferation.
Pallai R, Bhaskar A, Sodi V, Rice LM.
europepmc +5 more sources
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. [PDF]
Cancer Research, 2013 Protein phosphatase 2A (PP2A) complexes function as tumor suppressors by inhibiting the activity of several critical oncogenic signaling pathways.
A. Khanna, J. Pimanda, J. Westermarck
semanticscholar +5 more sources
Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer
Cancer Medicine, 2018 Preoperative (chemo)radiotherapy, (C)RT, is an essential part of the treatment of rectal cancer patients, but tumor response to this therapy among patients is variable. Thus far, there are no clinical biomarkers that could be used to predict response to (
Eva‐Maria Birkman +8 more
doaj +2 more sources
Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin. [PDF]
World J Gastrointest Oncol, 2023 Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a newly discovered oncogene. It is an active cell proliferation regulatory factor that inhibits tumor apoptosis in gastric cancer (GC) cells. CIP2A is functionally related to chemoresistance in various types of tumors according to recent studies.
Zhao YX +5 more
europepmc +3 more sources
Respiratory Research, 2019 Lung cancer (LC) has the highest relative risk of development as a comorbidity of chronic obstructive pulmonary disease (COPD). The molecular mechanisms that mediate chronic inflammation and lung function impairment in COPD have been identified in LC ...
Cassandra P. Nader +3 more
doaj +2 more sources
Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers
International Journal of Cancer, 2016 Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A), a recently identified oncogene, has emerged as a potential drug target for a range of different tumor types. High CIP2A expression has been reported in almost all solid organ cancers and in some hematological tumors and is associated with high grade and poor prognosis.
A. Khanna, J. Pimanda
semanticscholar +4 more sources
Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells [PDF]
, 2013 Breast cancer is the most common female cancerous disease and the second most cause of cancer death in women. About 20-30% of these tumors exhibit an amplification of the HER2/ErbB2 receptor, which is coupled to a more aggressive and invasive growth of ...
Brobeil, Alexander +4 more
core +21 more sources
CIP2A promotes inflammation and exacerbates osteoarthritis by targeting CEMIP [PDF]
Cellular & Molecular Biology LettersBackground Osteoarthritis (OA) is a chronic joint disease characterized by cartilage degeneration with unclear pathogenic mechanism. This study aims to discuss the regulatory role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in OA ...
Jingyue Su +8 more
doaj +2 more sources